The cost-effectiveness of harm reduction

International Journal of Drug Policy

Volumn 26, Issue S1, 2015, Pages S5-S11

  Wilson, David P ^a   Donald, Braedon ^a   Shattock, Andrew J ^a   Wilson, David ^b   Fraser Hurt, Nicole ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b WORLD BANK   (United States)

Author keywords

Cost effectiveness; Harm reduction; HIV; People who inject drugs

Indexed keywords

ANTIRETROVIRUS AGENT; METHADONE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

COST CONTROL; COST EFFECTIVENESS ANALYSIS; DRUG COST; EPIDEMIC; HARM REDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; INVESTMENT; NEEDLE SYRINGE PROGRAM; NOTE; OPIATE ADDICTION; OPIATE SUBSTITUTION TREATMENT; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RISK REDUCTION; SCALE UP; SUBSTITUTION THERAPY; VIRUS TRANSMISSION; COMPLICATION; COST BENEFIT ANALYSIS; ECONOMICS; HEALTH; HIV INFECTIONS; ORGANIZATION AND MANAGEMENT; PREVALENCE; PREVENTIVE HEALTH SERVICE; PROCEDURES; SUBSTANCE ABUSE;

ANTI-HIV AGENTS; COST-BENEFIT ANALYSIS; GLOBAL HEALTH; HARM REDUCTION; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; OPIATE SUBSTITUTION TREATMENT; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84923319563     PISSN: 09553959     EISSN: 18734758     Source Type: Journal    
DOI: 10.1016/j.drugpo.2014.11.007     Document Type: Note

References (87)

1. Alistar S.S., Owens D.K., Brandeau M.L. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: A modeling analysis for Ukraine. PLoS Medicine 2011, 8(3):e1000423.
2. Anglemyer A., Rutherford G.W., Egger M., Siegfried N. Antiretroviral therapy for prevention of HIV transmission in HIV-discordant couples. Cochrane Database of Systematic Reviews 2011, (8):CD009153.
3. Attia S., et al. Sexual transmission of HIV according to viral load and antiretroviral therapy: Systematic review and meta-analysis. AIDS 2009, 23(11):1397-1404.
4. Ball J.C., et al. Reducing the risk of AIDS through methadone maintenance treatment. Journal of Health and Social Behavior 1988, 29(3):214-226.
5. Bastos F.I., Strathdee S.A. Evaluating effectiveness of syringe exchange programmes: Current issues and future prospects. Social Science & Medicine 2000, 51(12):1771-1782.
6. Belani H.K., Muennig P.A. Cost-effectiveness of needle and syringe exchange for the prevention of HIV in New York City. Journal of HIV/AIDS & Social Services 2008, 7(3):229-240.
7. Beyrer C., et al. Time to act: A call for comprehensive responses to HIV in people who use drugs. Lancet 2010, 376(9740):551-563.
8. Bridge J., Lazarus J.V., Atun R. H.I.V. epidemics and prevention responses in Asia and Eastern Europe: Lessons to be learned?. AIDS 2010, 24:S86-S94.
9. Bruggmann P., Grebely J. Prevention, treatment and care of hepatitis C virus infection among people who inject drugs. International Journal of Drug Policy 2015, 26:S22-S26.
10. Choopanya K., et al. Risk factors and HIV seropositivity among injecting drug users in Bangkok. AIDS 1991, 5(12):1509-1513.
11. Choopanya K., et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013, 381(9883):2083-2090.
12. Cohen M.S., et al. Prevention of HIV-1 infection with early antiretroviral therapy. The New England Journal of Medicine 2011, 365(6):493-505.
13. Craig A.E.A. Spending of HIV resources in Asia and Eastern Europe: Systematic review reveals the need to shift funding allocations towards priority populations 2014.
14. Craig A.P., et al. HIV antiretroviral prophylaxis for injecting drug users. Lancet 2013, 382(9895):854-855.
15. Degenhardt L., et al. Prevention of HIV infection for people who inject drugs: Why individual, structural, and combination approaches are needed. Lancet 2010, 376(9737):285-301.
16. Des Jarlais D.C., et al. HIV incidence among injecting drug users in New York City syringe-exchange programmes. Lancet 1996, 348(9033):987-991.
17. Des Jarlais D.C., et al. HIV incidence among injection drug users in New York City, 1990 to 2002: Use of serologic test algorithm to assess expansion of HIV prevention services. American Journal of Public Health 2005, 95(8):1439-1444.
18. Des Jarlais D.C., et al. High coverage needle/syringe programs for people who inject drugs in low and middle income countries: A systematic review. BMC Public Health 2013, 13.
19. El-Bassel N., et al. Drug use as a driver of HIV risks: Re-emerging and emerging issues. Current Opinion in HIV and AIDS 2014, 9(2):150-155.
20. Emmanuel F., et al. Factors associated with an explosive HIV epidemic among injecting drug users in Sargodha, Pakistan. Journal of Acquired Immune Deficiency Syndromes 2009, 51(1):85-90.
21. Gibson D.R., Flynn N.M., Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 2001, 15(11):1329-1341.
22. Gowing L., et al. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database of Systematic Reviews 2011, (8):CD004145.
23. Guinness L., et al. The cost-effectiveness of consistent and early intervention of harm reduction for injecting drug users in Bangladesh. Addiction 2010, 105(2):319-328.
24. Hall W., et al. Compulsory detention: Forced detoxification and enforced labour are not ethically acceptable or effective ways to treat addiction. Addiction 2012, 107(11):1891-1893.
25. Hammett T. Evaluation of HIV prevention interventions for people who inject drugs in low- and middle-income countries - the current and future state of the art. International Journal of Drug Policy 2014, 25(3):336-339.
26. Heimer R. Syringe exchange programs: Lowering the transmission of syringe-borne diseases and beyond. Public Health Reports 1998, 113(Suppl. 1):67-74.
27. Hubbard R.L., et al. Role of drug-abuse treatment in limiting the spread of AIDS. Reviews of Infectious Diseases 1988, 10(2):377-384.
28. Hurley S.F., Jolley D.J., Kaldor J.M. Effectiveness of needle-exchange programmes for prevention of HIV infection. Lancet 1997, 349(9068):1797-1800.
29. International, H.R. The global state of harm reduction: Towards an integrated response. London, United Kingdom 2012.
30. Ivsins A., Chow C., Marsh D., Macdonald S., Stockwell T., Vallance K. Drug use trends in Victoria and Vancouver, and changes in injection drug use after the closure of Victoria's fixed site needle exchange 2010, Centre for Addictions Research of British Columbia.
31. Jenkins C., et al. Measuring the impact of needle exchange programs among injecting drug users through the National Behavioural Surveillance in Bangladesh. AIDS Education and Prevention 2001, 13(5):452-461.
32. Jones L., Pickering L., Sumnall H., McVeigh J., Bellis A. A review of the effectiveness and cost-effectiveness of needle and syringe programs for injecting drug users 2008, Centre for Pulic Health, Liverpool John Moores University.
33. Kahn J.G., et al. Cost-effectiveness of antiretroviral therapy for prevention. Current HIV Research 2011, 9(6):405-415.
34. Kelley C.F., Haaland R.E., Patel P., Evans-Strickfaden T., Farshy C., Hanson D., et al. HIV-1 RNA rectal shedding is reduced in men with low plasma HIV-1 RNA viral loads and is not enhanced by sexually transmitted bacterial infections of the rectum. Journal of Infectious Diseases 2011, 204(5):761-767.
35. Kidorf M., King V.L. Expanding the public health benefits of syringe exchange programs. Canadian Journal of Psychiatry 2008, 53(8):487-495.
36. Kwon J.A., et al. The impact of needle and syringe programs on HIV and HCV transmissions in injecting drug users in Australia: A model-based analysis. Journal of Acquired Immune Deficiency Syndromes 2009, 51(4):462-469.
37. Kwon J.A., et al. Estimating the cost-effectiveness of needle-syringe programs in Australia. AIDS 2012, 26(17):2201-2210.
38. Lacombe K., Rockstroh J. HIV and viral hepatitis coinfections: Advances and challenges. Gut 2012, 61(Suppl. 1):pi47-pi58.
39. Lert F., Kazatchkine M.D. Antiretroviral HIV treatment and care for injecting drug users: An evidence-based overview. International Journal of Drug Policy 2007, 18(4):255-261.
40. Li J., et al. The epidemiological impact and cost-effectiveness of HIV testing: Antiretroviral treatment and harm reduction programs. AIDS 2012, 26(16):2069-2078.
41. Lohse N., et al. Survival of persons with and without HIV infection in Denmark, 1995-2005. Annals of Internal Medicine 2007, 146(2):87-95.
42. Long E.F., et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS 2006, 20(17):2207-2215.
43. Loubiere S., et al. Economic evaluation of ART in resource-limited countries. Current Opinion in HIV and AIDS 2010, 5(3):225-231.
44. Lurie P., et al. An economic analysis of needle exchange and pharmacy-based programs to increase sterile syringe availability for injection drug users. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 1998, 18:S126-S132.
45. MacArthur G.J., et al. Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. British Medical Journal 2012, 345:pe5945.
46. Marseille E., et al. HIV prevention costs and program scale: Data from the PANCEA project in five low and middle-income countries. BMC Health Services Research 2007, 7:108.
47. Mathers B.M., et al. HIV prevention, treatment, and care services for people who inject drugs: A systematic review of global, regional, and national coverage. Lancet 2010, 375(9719):1014-1028.
48. Menzies N.A., et al. The cost of providing comprehensive HIV treatment in PEPFAR-supported programs. AIDS 2011, 25(14):1753-1760.
49. Mumtaz G.R., et al. HIV among people who inject drugs in the Middle East and North Africa: Systematic review and data synthesis. PLoS Medicine 2014, 11(6).
50. Naning H., Kerr C., Kamarulzaman A., Dahlui M., Ng Chiu-Wan, Osornprasop S., Wilson D.P. Cost-effectiveness and return on investment of HIV harm reduction Programmes for people who inject drugs in Malaysia 2013 2013.
51. Ni M.J., et al. Net financial benefits of averting HIV infections among people who inject drugs in Urumqi, Xinjiang, Peoples Republic of China (2005-2010). BMC Public Health 2012, 12:572.
52. OECD Aid to Developing countries rebounds in 2013 to reach an all-time high 2014, OECD, Editor.
53. Open Society Institute Breaking down barriers: Lessons on providing HIV treatment to injection drug users 2004, Open Society Institute, New York, USA.
54. Palmateer N., et al. Evidence for the effectiveness of sterile injecting equipment provision in preventing hepatitis C and human immunodeficiency virus transmission among injecting drug users: A review of reviews. Addiction 2010, 105(5):844-859.
55. Quinn T.C., et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. New England Journal of Medicine 2000, 342(13):921-929.
56. Remme M., et al. Paying girls to stay in school: A good return on HIV investment?. The Lancet 2012, 379(9832):p2150.
57. Remme M., et al. Financing structural interventions: Going beyond HIV-only value for money assessments. AIDS 2014, 28(3):425-434.
58. Sarkar S., et al. Rapid spread of HIV among injecting drug users in north-eastern states of India. Bulletin on Narcotics 1993, 45(1):91-105.
59. Schwartlander B., et al. Towards an improved investment approach for an effective response to HIV/AIDS. Lancet 2011, 377(9782):2031-2041.
60. Stimson G.V. Syringe-exchange programmes for injecting drug users. AIDS 1989, 3(5):253-260.
61. Strathdee S.A., et al. Towards combination HIV prevention for injection drug users: Addressing addictophobia, apathy and inattention. Current Opinion in HIV and AIDS 2012, 7(4):320-325.
62. Strathdee S.A., Beletsky L., Kerr T. HIV, drugs and the legal environment. International Journal of Drug Policy 2015, 26:S27-S32.
63. Tilson H.A.A., Bozzette S. Preventing HIV infection among injecting drug users in high-risk countries: An assessment of the evidence. 2007, Institute of Medicine, Washington, DC.
64. TRan B.X., Nguyen L.T. Impact of methadone maintenance on health utility: Health care utilization and expenditure in drug users with HIV/AIDS. International Journal of Drug Policy 2013, 24(6):e105-e110.
65. Tran B.X., et al. The cost-effectiveness and budget impact of Vietnam's methadone maintenance treatment programme in HIV prevention and treatment among injection drug users. Global Public Health 2012, 7(10):1080-1094.
66. UNAIDS UNAIDS report on the global AIDS epidemic 2012, http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2012/gr2012/20121120_UNAIDS_Global_Report_2012_en.pdf.
67. UNAIDS Global Report UNAIDS report on the global AIDS epidemic 2013 2013, UNAIDS.
68. UNODC Scientific Consultation: Vienna, 11 March 2014 Science addressing drugs and HIV: State of the Art of Harm Reduction. A Scientific Statement 2014.
69. Van Den Berg C., et al. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007, 102(9):1454-1462.
70. Vickerman P., et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sexually Transmitted Infections 2006, 33(10 Suppl.):S89-S102.
71. Vickerman P., Miners A., Williams J. Assessing the cost-effectiveness of interventions linked to needle and syringe programmes for injecting drug users: An economic modelling report 2008.
72. Wammes J.J., et al. Cost-effectiveness of methadone maintenance therapy as HIV prevention in an Indonesian high-prevalence setting: A mathematical modeling study. International Journal of Drug Policy 2012, 23(5):358-364.
73. WHO Asessessment of compulsory treatment of people who use drugs in Cambodia, China, Malaysia and Vietnam: An application of selected human rights principles 2009, WHO Western Pacific Region.
74. WHO, U., UNAIDS WHO, UNODC, UNAIDS Technical Guide for countries to set targets for universal access to HIV prevention, treatment and care for injecting drug users 2009, World Health Organization.
75. WHO Social contexts of access to treatment and care for HIV, hepatitis C and tuberculosis among people who inject drugs in European cities 2012.
76. Wilson D.P. Evidence is still required for treatment as prevention for riskier routes of HIV transmission. AIDS 2010, 24:2891-2893.
77. Wilson D., Fraser-Hurt N. The economics and financing of harm reduction. IHRA 2013.
78. Wilson D.P., et al. Relation between HIV viral load and infectiousness: A model-based analysis. Lancet 2008, 372(9635):314-320.
79. Wilson D., et al. The economics, financing and implementation of HIV treatment as prevention: What will it take to get there?. AJAR - African Journal of AIDS Research 2014, 13(2):109-119.
80. Wodak A. Lessons from the first international review of the evidence for needle syringe programs: The band still plays on. Substance Use & Misuse 2006, 41(6-7):837-839.
81. Wodak A., Cooney A. Effectiveness of sterile needle and syringe programs. International Journal of Drug Policy 2005, 16(Supplement 1):31-44.
82. Wodak A., Maher L. The effectiveness of harm reduction in preventing HIV among injecting drug users. NSW Public Health Bulletin 2010, 21(3-4).
83. Wood E., et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS 2002, 16(6):941-943.
84. World Health Organization WHO Injecting drug use 2013, Available from: http://www.who.int/hiv/topics/idu/en/index.html [accessed 07.17.13].
85. Wu W.Z. Arguments in favour of compulsory treatment of opioid dependence. Bulletin of the World Health Organization 2013, 91(2):142-145.
86. Wu Z.Y., Shi C.X., Detels R. Addressing injecting drug use in Asia and Eastern Europe. Current HIV/AIDS Reports 2013, 10(2):187-193.
87. Yancovitz S.R., et al. A randomized trial of an interim methadone maintenance clinic. American Journal of Public Health 1991, 81(9):1185-1191.